KR102104197B9 - 난소암의 치료를 위한 항혈관신생 요법 - Google Patents

난소암의 치료를 위한 항혈관신생 요법

Info

Publication number
KR102104197B9
KR102104197B9 KR1020187035833A KR20187035833A KR102104197B9 KR 102104197 B9 KR102104197 B9 KR 102104197B9 KR 1020187035833 A KR1020187035833 A KR 1020187035833A KR 20187035833 A KR20187035833 A KR 20187035833A KR 102104197 B9 KR102104197 B9 KR 102104197B9
Authority
KR
South Korea
Prior art keywords
treatment
ovarian cancer
angiogenesis therapy
angiogenesis
therapy
Prior art date
Application number
KR1020187035833A
Other languages
English (en)
Other versions
KR102104197B1 (ko
KR20180135101A (ko
Inventor
제이콥 듀퐁
코넬리아 얼
Original Assignee
제넨테크, 인크.
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44476669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102104197(B9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 제넨테크, 인크., 에프. 호프만-라 로슈 아게 filed Critical 제넨테크, 인크.
Publication of KR20180135101A publication Critical patent/KR20180135101A/ko
Application granted granted Critical
Publication of KR102104197B1 publication Critical patent/KR102104197B1/ko
Publication of KR102104197B9 publication Critical patent/KR102104197B9/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q99/00—Subject matter not provided for in other groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Business, Economics & Management (AREA)
  • Theoretical Computer Science (AREA)
  • General Business, Economics & Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187035833A 2010-02-23 2011-02-22 난소암의 치료를 위한 항혈관신생 요법 KR102104197B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US30709510P 2010-02-23 2010-02-23
US61/307,095 2010-02-23
US35123110P 2010-06-03 2010-06-03
US61/351,231 2010-06-03
US36005910P 2010-06-30 2010-06-30
US61/360,059 2010-06-30
US201161439819P 2011-02-04 2011-02-04
US61/439,819 2011-02-04
KR1020187006794A KR20180028561A (ko) 2010-02-23 2011-02-22 난소암의 치료를 위한 항혈관신생 요법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187006794A Division KR20180028561A (ko) 2010-02-23 2011-02-22 난소암의 치료를 위한 항혈관신생 요법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197037761A Division KR20190143480A (ko) 2010-02-23 2011-02-22 난소암의 치료를 위한 항혈관신생 요법

Publications (3)

Publication Number Publication Date
KR20180135101A KR20180135101A (ko) 2018-12-19
KR102104197B1 KR102104197B1 (ko) 2020-04-24
KR102104197B9 true KR102104197B9 (ko) 2022-10-21

Family

ID=44476669

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020197037761A KR20190143480A (ko) 2010-02-23 2011-02-22 난소암의 치료를 위한 항혈관신생 요법
KR1020127021909A KR101839161B1 (ko) 2010-02-23 2011-02-22 난소암의 치료를 위한 항혈관신생 요법
KR1020187035833A KR102104197B1 (ko) 2010-02-23 2011-02-22 난소암의 치료를 위한 항혈관신생 요법
KR1020187006794A KR20180028561A (ko) 2010-02-23 2011-02-22 난소암의 치료를 위한 항혈관신생 요법

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020197037761A KR20190143480A (ko) 2010-02-23 2011-02-22 난소암의 치료를 위한 항혈관신생 요법
KR1020127021909A KR101839161B1 (ko) 2010-02-23 2011-02-22 난소암의 치료를 위한 항혈관신생 요법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187006794A KR20180028561A (ko) 2010-02-23 2011-02-22 난소암의 치료를 위한 항혈관신생 요법

Country Status (20)

Country Link
US (7) US8778340B2 (ko)
EP (3) EP3696194A1 (ko)
JP (6) JP2013520442A (ko)
KR (4) KR20190143480A (ko)
CN (2) CN110227154A (ko)
AR (1) AR080244A1 (ko)
AU (5) AU2011221229B2 (ko)
BR (1) BR112012020700A8 (ko)
CA (2) CA2930248A1 (ko)
CL (1) CL2012002326A1 (ko)
CO (1) CO6592072A2 (ko)
IL (2) IL221058B (ko)
MA (1) MA34059B1 (ko)
MX (3) MX369170B (ko)
PH (1) PH12016501728A1 (ko)
RU (1) RU2012140447A (ko)
SG (2) SG183414A1 (ko)
TW (2) TWI457135B (ko)
UA (1) UA114277C2 (ko)
WO (1) WO2011106300A2 (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
ES2707580T3 (es) 2011-09-23 2019-04-04 Oncomed Pharm Inc Agentes de unión a VEGF/DLL4 y usos de los mismos
US20150098988A1 (en) * 2012-03-13 2015-04-09 Hoffmann-La Roche Inc. Combination therapy for the treatment of ovarian cancer
HUE056217T2 (hu) 2012-07-13 2022-02-28 Roche Glycart Ag Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében
SG11201500903XA (en) * 2012-08-07 2015-03-30 Genentech Inc Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
PE20210168A1 (es) 2014-02-10 2021-01-28 Merck Patent Gmbh INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß)
AU2015242788B2 (en) * 2014-04-04 2018-10-25 Taiho Pharmaceutical Co., Ltd. Anti-tumor drug containing taxane compound, and anti-tumor effect enhancer
AU2015256052A1 (en) * 2014-05-07 2016-11-10 Medimmune, Llc Methods of using anti-Ang2 antibodies
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3169801A1 (en) 2014-07-14 2017-05-24 F. Hoffmann-La Roche AG Diagnostic methods and compositions for treatment of glioblastoma
MX2017006201A (es) * 2014-11-14 2017-07-31 Genentech Inc Respuesta de prediccion a un antagonista de vegf.
WO2017049149A1 (en) * 2015-09-17 2017-03-23 Immunogen, Inc. Therapeutic combinations comprising anti-folr1 immunoconjugates
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
TW201713360A (en) * 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
EP3272771A1 (en) * 2016-07-22 2018-01-24 Centre National De La Recherche Scientifique Treatment for use for preventing metastasis in a subject exposed to cancer treatment inducing p38 activation
EP3777889A4 (en) * 2018-03-26 2022-01-26 Shanghai Yile Biotechnology Co., Ltd. USE OF A PROBDNF REGULATOR IN B-LYMPHOCYTE ASSOCIATED DISEASES
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CN115814076A (zh) * 2021-07-01 2023-03-21 江苏先声药业有限公司 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
WO2023196153A1 (en) * 2022-04-04 2023-10-12 Merck Sharp & Dohme Llc Methods for treating cancer, an infectious disease or an infection using a combination of a tigit antagonist, a pd-1 antagonist, and a vegf antagonist

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US991302A (en) * 1910-03-28 1911-05-02 Frederick G Hepburn Waste-supporter.
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
RO119721B1 (ro) 1992-10-28 2005-02-28 Genentech Inc. Antagonişti ai factorului de creştere al celulelor vasculare endoteliale
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
AU716785B2 (en) 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
ATE476664T1 (de) 1997-04-07 2010-08-15 Genentech Inc Anti-vegf antikörper
EP1325932B9 (en) * 1997-04-07 2006-07-19 Genentech, Inc. Anti-vegf antibodies
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
AU784285B2 (en) 1999-12-24 2006-03-02 Genentech Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
NZ521540A (en) 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
CA2838062C (en) 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
KR20180132969A (ko) * 2003-05-30 2018-12-12 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
PT2322556E (pt) * 2004-09-03 2016-02-15 Genentech Inc Antagonistas humanizados anti-beta7 e suas utilizações
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
SG175597A1 (en) * 2007-10-30 2011-11-28 Genentech Inc Antibody purification by cation exchange chromatography
DK2361085T4 (en) 2008-11-22 2018-10-08 Hoffmann La Roche USE OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERY TO TREAT CANCER CANCER

Also Published As

Publication number Publication date
PH12016501728A1 (en) 2018-02-12
AU2015210479A1 (en) 2015-09-03
BR112012020700A8 (pt) 2018-01-02
RU2012140447A (ru) 2014-03-27
CA2787952A1 (en) 2011-09-01
CN103237810A (zh) 2013-08-07
SG10201401123VA (en) 2014-08-28
CO6592072A2 (es) 2013-01-02
TW201526912A (zh) 2015-07-16
WO2011106300A2 (en) 2011-09-01
KR20130010884A (ko) 2013-01-29
CN110227154A (zh) 2019-09-13
KR20190143480A (ko) 2019-12-30
BR112012020700A2 (pt) 2017-03-21
AU2011221229B2 (en) 2015-06-18
AU2019210484A1 (en) 2019-08-15
KR102104197B1 (ko) 2020-04-24
US20230226179A1 (en) 2023-07-20
UA114277C2 (uk) 2017-05-25
TWI457135B (zh) 2014-10-21
CA2930248A1 (en) 2011-09-01
KR101839161B1 (ko) 2018-03-16
US20160279241A1 (en) 2016-09-29
AU2019203466A1 (en) 2019-06-06
US20180344847A1 (en) 2018-12-06
EP3696194A1 (en) 2020-08-19
JP2013173775A (ja) 2013-09-05
JP2013520442A (ja) 2013-06-06
US20140178371A1 (en) 2014-06-26
IL221058B (en) 2018-04-30
JP2017193551A (ja) 2017-10-26
KR20180135101A (ko) 2018-12-19
KR101839161B9 (ko) 2022-10-18
JP2020196719A (ja) 2020-12-10
IL258612A (en) 2018-06-28
CA2787952C (en) 2016-07-26
MX369170B (es) 2019-10-30
CL2012002326A1 (es) 2012-11-30
JP2016020354A (ja) 2016-02-04
US20210052728A1 (en) 2021-02-25
AU2011221229A1 (en) 2012-08-16
AU2017204320A1 (en) 2017-07-13
SG183414A1 (en) 2012-09-27
AR080244A1 (es) 2012-03-21
TW201138819A (en) 2011-11-16
JP6184733B2 (ja) 2017-08-23
EP3064509A2 (en) 2016-09-07
TWI619509B (zh) 2018-04-01
EP3064509A3 (en) 2016-11-02
US8778340B2 (en) 2014-07-15
KR20180028561A (ko) 2018-03-16
IL258612B (en) 2022-01-01
AU2017204320B2 (en) 2019-02-21
MX2012009554A (es) 2012-11-23
MX2019000425A (es) 2023-04-27
WO2011106300A3 (en) 2011-12-15
EP2539367A2 (en) 2013-01-02
MA34059B1 (fr) 2013-03-05
JP2018199683A (ja) 2018-12-20
US20110206662A1 (en) 2011-08-25
US20170143826A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
IL258612B (en) An anti-angiogenic drug for the treatment of ovarian cancer
HRP20190046T1 (hr) Kombinirana terapija za liječenje raka
SG10201508495VA (en) Combination treatment of cancer
IL263781A (en) Combined treatment of ovarian cancer
EP2830633A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
HK1214128A1 (zh) 癌症的治療
EP2807111A4 (en) MULTIFUNCTIONAL NANOMATERIALS FOR THE TREATMENT OF CARCINOMES
HK1185874A1 (zh) 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺
ZA201300762B (en) Novel combination therapy for the treatment of cancer
GB201217892D0 (en) Treatment of cancer
IL275636A (en) Medical combination for cancer treatment
HK1204956A1 (en) Treatment of cancer
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
EP2849786A4 (en) METHOD FOR THE TREATMENT OF GASCULAR CANCER
GB201217890D0 (en) Treatment of cancer
ZA201307677B (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
IL233495A0 (en) Combination for cancer treatment
GB201208296D0 (en) Treatment of cancer
GB201017354D0 (en) Treatment of cancer
GB201222950D0 (en) Combination treatment of cancer
GB201222949D0 (en) Combination Treatment of Cancer
GB201017356D0 (en) Combination treatment of cancer
GB201121791D0 (en) Combination treatment of cancer

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
X701 Decision to grant (after re-examination)
J204 Request for invalidation trial [patent]
J204 Request for invalidation trial [patent]
J301 Trial decision

Free format text: TRIAL NUMBER: 2021100002402; TRIAL DECISION FOR INVALIDATION REQUESTED 20210810

Effective date: 20220429

J121 Written withdrawal of request for trial
J122 Written withdrawal of action (patent court)